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Background: IN.PACT Global was developed to expand the appraisal of the IN.PACT Admiral Drug-coated Balloon (Medtronic) in the 
treatment of real-world PAD patients, including those with lesions greater than 15 cm in length.
methods: IN.PACT Global is a prospective, independently adjudicated and monitored, multi-center, international, 1500-patient, single-arm 
study on DCB revascularization of femoro-popliteal stenosis and occlusions with a minimum length of 2 cm. One-year results from the first 
655 patients enrolled are presented. The majority had severe (58.2%) or moderate (27.3%) claudication or ischemic rest pain (10.9%) at 
baseline.The mean lesion length was 12.23 cm; 35.8% of lesions were total occlusions, 21.4% of lesions represented in-stent restenosis. 
The primary endpoint was clinically-driven target lesion revascularization (CD-TLR) at 12-months. Additional long lesion data from the core 
lab imaging cohort will be available prior to ACC 2015.
results: At 12-months, the rate of CD-TLR was 8.7%. An analysis by lesion length on the subset of subjects (N=514) with unilateral limb 
treatment of single lesions was also performed. The CD-TLR rate in lesion lengths greater than 15 cm was 11.5% (22/191), confirming the 
performance of the IN.PACT Admiral DCB in long lesions.
conclusion:  Preliminary results from IN.PACT Global indicate that the IN.PACT Admiral DCB is safe and efficacious in the treatment of 
real-world femoro-popliteal lesions and it continues to perform well in long lesions.
CD-TLR rates by Lesion Length
Lesion Length # Lesions(N=514) CD-TLR at 360 Days*
<5cm 87 2.5% (2/79)
5 to <10cm 108 5.2% (5/96)
10 to <15cm 99 8.2% (7/85)
15 to ≤18cm 51 12.2% (5/41)
>18 to ≤20cm 22 5.0% (1/20)
>20 to ≤24cm 46 4.7% (2/43)
>24cm 101 16.1% (14/87)
* CD-TLR rate is presented per lesion in subjects with lesion length data
Site-reported data from the July 17, 2014 interim snapshot from subjects with available lesion 
length data.
